Home Mavacamten
2022

Mavacamten

by cyb2025
R. Souza
Mavacamten

RODRIGO SOUZA
Biocatalysis and Organic Synthesis Group, Chemistry Institute, Federal University
of Rio de Janeiro, Rio de Janeiro, Brazils

This month we will present synthetic strategies towards the synthesis of mavacamten, used to treat obstructive hypertrophic cardiomyopathy by selective inhibition of cardiac myosin. Hypertrophic cardiomyopathy (HCM) is a condition in which the heart becomes thickened without an obvious cause, resulting in the heart being less able to pump blood effectively and also may cause electrical conduction problems.

 

 

ABOUT THE AUTHOR

Rodrigo Souza – Since I started my independent career, I have pursuit the development of new technologies to guide research by innovative ideas. We have been working at Federal University of Rio de Janeiro on the establishment of continuous flow technology for active pharmaceutical ingredients (API) synthesis in Brazil, showing that is possible to reduce costs on production allowing the reduction of the final price of the medicine.

Latest issue

September / October 2025

View Issue

Archive

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt!

Chemistry Today - Archive
Go to archive

Content from magazine

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores.
View all content

The most read

@2019 - All Right Reserved. Designed and Developed by PenciDesign

Login